<DOC>
	<DOC>NCT00601328</DOC>
	<brief_summary>The objective of this study was to assess the bioequivalence of Roxane Laboratories' Calcitriol capsules, 0.25 mcg, to ROCALTROLÂ® capsules, 0.25 mcg (Roche) using a single-dose, 2-treatment, 2-period, crossover design, under fasting conditions</brief_summary>
	<brief_title>Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Hypocalcemia</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Calcitriol or any comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>